• Behavioral Health
  • Clinical Insights
  • Treatment

August 2023 drug trend report

Aug 2nd, 2023

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market.

Brand name drug launches*

Uzedy

  • Indicated for: Treatment of schizophrenia in adults.
  • Dosage form: Extended-release injectable suspension.
  • Status: Available now.

Abilify Asimtuffii

  • Indicated for: Treatment of schizophrenia in adults and as a maintenance monotherapy treatment of bipolar I disorder in adults.
  • Dosage form: Long-acting injectable.
  • Status: Available now.

Brixadi

  • Indicated for: Treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
  • Dosage form: Extended-release injectable.
  • Status: Expected September of 2023 (Genoa is working to become a REMS-certified pharmacy to dispense Brixadi).

Generic drug launches*

Vyvanse capsules and chewable tablets (Lisdexamfetamine Dimesylate)

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older.
  • Status: Expected August 25, 2023.

Current drug shortages*

Brand:

Adderall

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) and/or narcolepsy.
  • Status: Estimated recovery December 2023.

Mounjaro

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Ozempic

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Generic:

Lorazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Estimated recovery August 2023

Clonazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Recovery TBD.

Divalproex DR 500mg

  • Indicated for: Treatment of bipolar disorder, migraines, and other indications.
  • Status: Recovery TBD.

*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Treatment
4 things to know about Spravato® (Intranasal esketamine)

On January 21, 2025, the FDA announced the approval of Spravato® nasal spray as a monotherapy treatment for treatment-resistant depression (TRD), making this medication the first and only monotherapy option...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa’s 2024 Art Celebration: Celebrating the healing power of creativity

“I’ve always expressed myself through my art and learned to use my creativity to inspire others”, says Genoa Healthcare 2024 Art Celebration participant Shanelle G. Genoa’s annual Art Celebration invites...

Partner with Genoa
  • Behavioral Health
  • Clinical Insights
  • Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression

Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...

  • Behavioral Health
  • Clinical Insights
  • Partnering with Genoa
CMS reporting now required: 4 ways Genoa can help

By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...